MD, CMO, Adaptimmune
Biography
Dr. Elliot Norry has served as Chief Medical Officer of Adaptimmune since January 2020 and he is a member of the Executive Team. Previously, Dr. Norry was Vice President of Clinical Safety in Pharmacovigilance at Adaptimmune, and leader of their ADP- A2AFP program. Prior to joining Adaptimmune, Dr. Norry served as Safety Development Leader at GSK, where he managed clinical safety for a broad range of early and late-stage products, including improvement activities for pazopanib for the treatment of soft tissue sarcoma. He was also chair of GSK’s Hepatic Safety Panel. Prior to his roles in the biotech and pharmaceutical industry, Dr. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania. He holds a B.A. from Columbia College and an M.D. from New York University. He performed his residency in Internal Medicine at Temple University Hospital in Philadelphia and his fellowships in gastroenterology at Thomas Jefferson University Hospital in Philadelphia.
Session Abstract – PMWC 2022 Silicon Valley
Track Chair:
Ira Mellman, Genentech
Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance
-
Sessions:
- Recent Advances in Cell-based Therapy (PANEL)
Session Chair: Sascha Rutz, Genentech
- Susie Jun, ArsenalBio
- Elliot Norry, Adaptimmune
- Tina Albertson, Lyell
- Hy Levitsky, Century Therapeutics - Patentability of Immunotherapies—Latest Developments
- Janet Xiao, Morrison & Foerster LLP - Cell-based Therapy Challenges (PANEL)
Session Chair: Sharon Benzeno, Adaptive Biotechnologies
- Arati Rao, PACT Pharma
- Hy Levitsky, Century Therapeutics
- Susie Jun, ArsenalBio - Next-generation Supply Chain For Cell & Gene Therapies (PANEL)
Session Chair: Sharon Benzeno, Adaptive Biotechnologies
- Tim Moore, Pact Pharma
- Heidi Hunter, Cardinal Health - Advances in Multi-Omic Spatial Profiling
Session Chair: Michael Rhodes, Nanostring
- Chris Corless, OHSU
- Biomarkers to Guide Immunotherapy
Session Chair: Danny Wells, ImmunAI
- Sanjeev Mariathasan, Genentech
- Klaus Lindpaintner, InterVenn Bioscience
- Lacey Padron, PICI - NaNots: A New Class of Immunotherapy
- Lou Hawthorne, Nanotics - Engineered Therapeutics (PANEL)
Session Chair: Paul Parren, Lava Therapeutics
- Sonja Schrepfer, UCSF
- Greg Lazar, Genentech
